Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANA CGM: Canagliflozin vs Sitagliptin in T2DM
NCT03267576Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change From Baseline in Glycemic Coefficient of Variation (CV) at Day 71. Started Oct 2017; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03267576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267576.